Working… Menu

A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03912532
Recruitment Status : Recruiting
First Posted : April 11, 2019
Last Update Posted : May 23, 2019
Information provided by (Responsible Party):
NGM Biopharmaceuticals, Inc

Brief Summary:
This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.

Condition or disease Intervention/treatment Phase
NASH - Nonalcoholic Steatohepatitis Biological: NGM282 Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of NGM282 Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Actual Study Start Date : April 1, 2019
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: NGM282 Dose 1
Administered by subcutaneous injection
Biological: NGM282

Experimental: NGM282 Dose 2
Administered by subcutaneous injection
Biological: NGM282

Experimental: NGM282 Dose 3
Administered by subcutaneous injection
Biological: NGM282

Placebo Comparator: Placebo
Administered by subcutaneous injection
Other: Placebo
Placebo for NGM282

Primary Outcome Measures :
  1. Proportion of participants achieving a histologic treatment effect (histologic response) as determined by the NASH CRN criteria after 24 weeks of NGM282 or matched placebo. [ Time Frame: 24 weeks ]
  2. Evaluate safety and tolerability of NGM282 in participants with NASH as a function of dose level after up to 24 weeks of treatment with NGM282 [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Proportion of subjects with improvement in liver fibrosis by ≥ 1 stage by CRN criteria [ Time Frame: 24 weeks ]
  2. Proportion of subjects achieving NASH resolution as determined by the NASH CRN criteria [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically confirmed NASH diagnosis as defined by the NASH CRN
  2. Total liver fat content of ≥ 10% as measured by MRI-PDFF

Exclusion Criteria:

  1. Clinically significant acute or chronic liver disease of an etiology other than NASH
  2. Evidence of drug-induced steatohepatitis secondary to amiodarone, corticosteroids, estrogens, methotrexate, tetracycline, or other medications known to cause hepatic steatosis
  3. History or presence of cirrhosis (compensated or decompensated) as determined by histology and/or relevant medical complications and/or laboratory parameters
  4. Prior or pending liver transplantation

Other protocol-defined inclusion/exclusion criteria could apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03912532

Layout table for location contacts
Contact: NGM Study Director (650) 243-5555

  Show 28 Study Locations
Sponsors and Collaborators
NGM Biopharmaceuticals, Inc
Layout table for investigator information
Study Director: NGM Study Director NGM Biopharmaceuticals

Layout table for additonal information
Responsible Party: NGM Biopharmaceuticals, Inc Identifier: NCT03912532     History of Changes
Other Study ID Numbers: 18-0108
First Posted: April 11, 2019    Key Record Dates
Last Update Posted: May 23, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases